• 1
    Ludwig J, Viggiano TR, McGill DB, Ott BJ. Nonalcoholic steatohepatitis. Mayo Clinic Proc 1980; 55:434438.
  • 2
    Farrell GC. Drugs and steatohepatitis. Semin Liver Dis 2002; 22:185194.
  • 3
    Dixon JB, O'Brien PE, Bhatal PS. A wider view on diagnostic criteria of nonalcoholic steatohepatitis (reply). Gastroenterology 2002; 122:841842.
  • 4
    Cairns SR, Peters TJ. Biochemical analysis of hepatic lipid in alcoholic and diabetic and control subjects. Clin Sci 1983; 65:645652.
  • 5
    Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121:91100.
  • 6
    Rashid M, Roberts EA. Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 2000; 30:4853.
  • 7
    Manton ND, Lipsett J, Moore DJ, Davidson GP, Bourne AJ, Couper RT. Non-alcoholic steatohepatitis in children and adolescents. Med J Aust 2000; 173:476479.
  • 8
    Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116:14131419.
  • 9
    Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123:745750.
  • 10
    Lee RG. Nonalcoholic steatohepatitis: tightening the morphological screws on a hepatic rambler. Hepatology 1995; 21:17421743.
  • 11
    Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107:11031109.
  • 12
    Contos MJ, Cales W, Sterling RK, Luketic VA, Shiffman ML, Mills AS, Fisher RA, et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 2001; 7:363373.
  • 13
    Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11:7480.
  • 14
    Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29:664669.
  • 15
    Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 2000; 32:689692.
  • 16
    Ong J, Younossi ZM, Reddy V, Price LL, Gramlich T, Mayes J, Boparai N. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl 2001; 7:797801.
  • 17
    Mathiesen UL, Franzen LE, Fryden A, Foberg U, Bodemar G. The clinical significance of slightly to moderately increased liver transaminase values in asymptomatic patients. Scand J Gastroenterol 1999; 34:8591.
  • 18
    Daniel S, Ben-Menachem T, Vasudevan G, Ma CK, Blumenkehl M. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol 1999; 94:30103014.
    Direct Link:
  • 19
    Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002; 122:16491657.
  • 20
    Sorbi D, McGill DB, Thistle JL, Therneau TM, Henry J, Lindor KD. An assessment of the role of liver biopsies in asymptomatic patients with chronic liver test abnormalities. Am J Gastroenterol 2000; 95:32063210.
    Direct Link:
  • 21
    Byron D, Minuk GY. Clinical hepatology: profile of an urban, hospital-based practice. Hepatology 1996; 24:813815.
  • 22
    Hilden M, Christoffersen P, Juhl E, Dalgaard JB. Liver histology in a ‘normal’ population: examination of 503 consecutive fatal traffic casualties. Scand J Gastroenterol 1977; 12:593597.
  • 23
    Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, Cristanini G, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132:112117.
  • 24
    Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12:11061110.
  • 25
    Andersen T, Gluud C. Liver morphology in morbid obesity: a literature study. Int J Obes Relat Metab Disord 1984; 8:97106.
  • 26
    Andersen T, Christoffersen P, Gluud C. The liver in consecutive patients with morbid obesity: a clinical, morphological, and biochemical study. Int J Obes Relat Metab Disord 1984; 8:107115.
  • 27
    Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, Khalil L, et al. Liver fibrosis in overweight patients. Gastroenterology 2000; 118:11171123.
  • 28
    García-Monzón C, Martín-Pérez E, Iacono OL, Fernández-Bermejo M, Majano PL, Apolinario A, Larraãga E, et al. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J Hepatol 2000; 33:716724.
  • 29
    Braillon A, Capron JP, Herve MA, Degott C, Quenum C. Liver in obesity. Gut 1985; 26:133139.
  • 30
    Klain J, Fraser D, Goldstein J, Peiser J, Avinoah E, Ovnat A, Charuzi I. Liver histology abnormalities in the morbidly obese. Hepatology 1989; 10:873876.
  • 31
    Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol 1989; 20:594598.
  • 32
    Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107:450455.
  • 33
    Falchuk KR, Fiske SC, Haggitt RC, Federman M, Trey C. Pericentral hepatic fibrosis and intracellular hyalin in diabetes mellitus. Gastroenterology 1980; 78:535541.
  • 34
    Silverman JF, Pories WJ, Caro JF. Liver pathology in diabetes mellitus and morbid obesity. Clinical, pathological, and biochemical considerations. Pathol Annual 1989; 24:275302.
  • 35
    Silverman JF, O'Brien KF, Long S, Leggett N, Khazanie PG, Pories WJ, Norris HT, et al. Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol 1990; 85:13491355.
  • 36
    Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30:13561362.
  • 37
    Saksena S, James O, Craig W, Day CP. Clinical and laboratory parameters predicting presence of NASH in unselected patients with NAFLD [Abstract]. Hepatology 2002; 36:222A.
  • 38
    Nanji AA, French SW, Freeman JB. Serum alanine aminotransferase to aspartate aminotransferase ratio and degree of fatty liver in morbidly obese patients. Enzyme 1986; 36:266269.
  • 39
    Caldwell SH, Hespenheide EE: Obesity and cryptogenic cirrhosis. In: LeuschnerU, JamesO, DancygierH, eds. Falk Symposium: Steatohepatitis (ASH and NASH). Volume 121. Norwell, MA: Kluwer Academic Publishers, 2001;151.
  • 40
    Propst A, Propst T, Zangerl G, Ofner D, Judmaier G, Vogel W. Prognosis and life expectancy in chronic liver disease. Dig Dis Sci 1995; 40:18051815.
  • 41
    Sasaki A, Horiuchi N, Hasegawa K, Uehara M. Mortality and causes of death in type 2 diabetic patients. A long-term follow-up study in Osaka District, Japan. Diabetes Res Clin Pract 1989; 7(Suppl):3340.
  • 42
    Hilden M, Juhl E, Thomsen AC, Christoffersen P. Fatty liver persisting for up to 33 years. A follow-up of the inversen-roholm liver biopsy material. Acta Med Scand 1973; 194:485489.
  • 43
    Nair S, Mason A, Eason J, Loss G, Perrillo RP. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? [erratum appears in Hepatology 2002; 36:774]. Hepatology 2002; 36:150155.
  • 44
    Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123:134140.
  • 45
    Ratziu V, Bonyhay L, Di Martino V, Charlotte F, Cavallaro L, Sayegh-Tainturier M-H, Giral P, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002; 35:14851493.
  • 46
    Ong JP, Younossi ZM. Is hepatocellular carcinoma part of the natural history of nonalcoholic steatohepatitis? [Letter; Comment] Gastroenterology 2002; 123:375378.
  • 47
    Strauss RS, Barlow SE, Dietz WH. Prevalence of abnormal serum aminotransferase values in overweight and obese adolescents. J Pediatr 2000; 136:727733.
  • 48
    Dulloo AG. Biomedicine. A sympathetic defense against obesity. Science 2002; 297:780781.
  • 49
    Bachman ES, Dhillon H, Zhang CY, Cinti S, Bianco AC, Kobilka BK, Lowell BB. betaAR signaling required for diet-induced thermogenesis and obesity resistance. Science 2002; 297:843845.
  • 50
    Caldwell SH, Harris DM, Patrie JT, Hespenheide EE. Is NASH underdiagnosed among African Americans? Am J Gastroenterol 2002; 97:14961500.
    Direct Link:
  • 51
    Santos L, Molina EG, Jeffers LJ, Reddy KR, Schiff ER. Prevalence of nonalcoholic steatohepatitis among ethnic groups [Abstract]. Gastroenterology 2001; 120:A117.
  • 52
    Squires RH, Lopez MJ. Steatohepatitis is a serious condition in Hispanic children [Abstract]. Hepatology 2000; 32:418A.
  • 53
    Kemmer NM, McKinney KH, Xiao S-Y, Singh H, Murray R, Abdo B, Eledrisi M, et al. High prevalence of NASH among Mexican American females with type II diabetes mellitus [Abstract]. Gastroenterology 2001; 120:A117.
  • 54
    Weston SR, Leyden WA, Murphy R, Manos MM, Bell BP, Bacchetti P, Bass NM, et al. Racial/ethnic distribution of newly diagnosed non-alcoholic fatty liver among participants of the chronic liver disease surveillance study [Abstract]. Hepatology 2002; 36:405A.
  • 55
    Perry AC, Applegate EB, Jackson ML, Deprima S, Goldberg RB, Ross R, Kempner L, et al. Racial differences in visceral adipose tissue but not anthropometric markers of health-related variables. J Appl Physiol 2000; 89:636643.
  • 56
    Struben VMD, Hespenheide EE, Caldwell S. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med 2000; 108:913.
  • 57
    Willner IR, Waters B, Patil SR, Reuben A, Morelli J, Riely CA. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 2001; 96:29572961.
    Direct Link:
  • 58
    Lee JH, Rhee PL, Lee JK, Lee KT, Kim JJ, Koh KC, Paik SW, et al. Role of hyperinsulinemia and glucose intolerance in the pathogenesis of nonalcoholic fatty liver in patients with normal body weight. Korean J Intern Med 1998; 13:1214.
  • 59
    Banerji MA, Faridi N, Atluri R, Chaiken RL, Lebovitz HE. Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men. J Clin Endocrinol Metab 1999; 84:137144.
  • 60
    Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, Cassader M, et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002; 35:367372.
  • 61
    Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35:373379.
  • 62
    Cortez-Pinto H, Camilo ME, Baptista A, De Oliveira AG, De Moura MC. Non-alcoholic fatty liver: another feature of the metabolic syndrome? Clin Nutr 1999; 18:353358.
  • 63
    Knobler H, Schattner A, Zhornicki T, Malnick SD, Keter D, Sokolovskaya N, Lurie Y, et al. Fatty liver—an additional and treatable feature of the insulin resistance syndrome. QJM 1999; 92:7379.
  • 64
    Ikai E, Ishizaki M, Suzuki Y, Ishida M, Noborizaka Y, Yamada Y. Association between hepatic steatosis, insulin resistance and hyperinsulinaemia as related to hypertension in alcohol consumers and obese people. J Hum Hypertens 1995; 9:101105.
  • 65
    Lobo RA, Carmina E. The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med 2000; 132:989993.
  • 66
    Kuczmarski RJ. Need for body composition information in elderly subjects. Am J Clin Nutr 1989; 50:11501157; discussion 1231–1235.
  • 67
    Powell EE, Searle J, Mortimer R. Steatohepatitis associated with limb lipodystrophy. Gastroenterology 1989; 97:10221024.
  • 68
    Garg A. Lipodystrophies. Am J Med 2000; 108:143152.
  • 69
    De Craemer D, Pauwels M, Van den Branden C. Alterations of peroxisomes in steatosis of the human liver: a quantitative study. Hepatology 1995; 22:744752.
  • 70
    Caldwell SH, Swerdlow RH, Khan EM, Iezzoni JC, Hespenheide EE, Parks JK, Parker WD Jr. Mitochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol 1999; 31:430434.
  • 71
    Sanyal AJ, Campbell-Sargent C, Mirshani F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120:11831192.
  • 72
    Bohan A, Droogan O, Nolan N, Mayne P, Bonham J, Thornton P, Farrell MA, et al. Mitochondrial DNA abnormalities without significant deficiency of intramitochondrial fatty acid β-oxidation enzymes in a well-defined subgroup of patients with nonalcoholic steatohepatitis (NASH) [Abstract]. Hepatology 2000; 32:387A.
  • 73
    Pessayre D, Berson A, Fromenty B, Mansouri A. Mitochondria in steatohepatitis. Semin Liver Dis 2001; 21:5769.
  • 74
    Wasserman JM, Thung SN, Berman R, Bodenheimer HC Jr, Sigal SH. Hepatic Weber-Christian disease. Semin Liver Dis 2001; 21:115118.
  • 75
    Van Steenbergen W, Lanckmans S. Liver disturbances in obesity and diabetes mellitus. Int J Obes Relat Metab Disord 1995; 19:S27S36.
  • 76
    Vila MR, Gamez J, Solano A, Playan A, Schwartz S, Santorelli FM, Cervera C, et al. Uncoupling protein-1 mRNA expression in lipomas from patients bearing pathogenic mitochondrial DNA mutations. Biochem Biophys Res Commun 2000; 278:800802.
  • 77
    Mansouri A, Gaou I, Fromenty B, Berson A, Letteron P, Degott C, Erlinger S, et al. Premature oxidative aging of hepatic mitochondrial DNA in Wilson's disease. Gastroenterology 1997; 113:599605.
  • 78
    Cotrim HP, Andrade ZA, Parana R, Portugal M, Lyra LG, Freitas LA. Nonalcoholic steatohepatitis: a toxic liver disease in industrial workers [see comments]. Liver 1999; 19:299304.
  • 79
    Redlich CA, West AB, Fleming L, True LD, Cullen MR, Riely CA. Clinical and pathological characteristics of hepatotoxicity associated with occupational exposure to dimethylformamide. Gastroenterology 1990; 99:748757.
  • 80
    Cotrim H, Freitas LA, Freitas C, Braga L, Parana R, Lyra L, Carvalho F. Nonalcoholic steatohepatitis in petrochemical workers: follow up of those removed from exposure area and those who remained [Abstract]. Hepatology 2002; 36:983A.
  • 81
    Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001; 21:2741.
  • 82
    Simon JB, Manley PN, Brien JF, Armstrong PW. Amiodarone hepatotoxicity simulating alcoholic liver disease. N Engl J Med 1984; 311:167172.
  • 83
    Cai Q, Bensen M, Greene R, Kirchner J. Tamoxifen-induced transient multifocal hepatic fatty infiltration. Am J Gastroenterol 2000; 95:277279.
    Direct Link:
  • 84
    Pinto HC, Baptista A, Camilo ME, de Costa EB, Valente A, de Moura MC. Tamoxifen-associated steatohepatitis—report of three cases. J Hepatol 1995; 23:9597.
  • 85
    Cote HC, Brumme ZL, Craib KJ, Alexander CS, Wynhoven B, Ting L, Wong H, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002; 346:811820.
  • 86
    Dahl MG, Gregory MM, Scheuer PJ. Liver damage due to methotrexate in patients with psoriasis. Br Med J 1971; 1:625630.
  • 87
    Cassagnou M, Boruchowicz A, Guillemot F, Gheyssens Y, Devisme L, Cortot A, Colombel JF. Hepatic steatosis revealing celiac disease: a case complicated by transitory liver failure [Letter]. Am J Gastroenterol 1996; 91:12911292.
  • 88
    Partin JS, Partin JC, Schubert WK, McAdams AJ. Liver ultrastructure in abetalipoproteinemia: evolution to micronodular cirrhosis. Gastroenterology 1974; 67:107118.
  • 89
    Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, Vianello L, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137:19.
  • 90
    Saltiel AR. New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell 2001; 104:517529.
  • 91
    Rothman DL, Magnusson I, Katz LD, Shulman RG, Shulman GI. Quantitation of hepatic glycogenolysis and gluconeogenesis in fasting humans with 13C NMR. Science 1991; 254:573576.
  • 92
    Magnusson I, Rothman DL, Katz LD, Shulman RG, Shulman GI. Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study. J Clin Invest 1992; 90:13231327.
  • 93
    Kim JK, Fillmore JJ, Chen Y, Yu C, Moore IK, Pypaert M, Lutz EP, et al. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci U S A 2001; 98:75227527.
  • 94
    Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest 1995; 95:24092415.
  • 95
    Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-α function. Nature 1997; 389:610614.
  • 96
    Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkβ. Science 2001; 293:16731677.
  • 97
    Hundal RS, Petersen KF, Mayerson A, Randhawa P, Inzucchi S, Shoelson SE, Shulman GI. Mechanisms by which high dose aspirin improves fasting and postprandial glucose metabolism in type 2 diabetes. J Clin Invest 2002; 109:13211326.
  • 98
    Barzilai N, Wang J, Massilon D, Vuguin P, Hawkins M, Rossetti L. Leptin selectively decreases visceral adiposity and enhances insulin action. J Clin Invest 1997; 100:31053110.
  • 99
    Saxena NK, Ikeda K, Rockey DC, Friedman SL, Anania FA. Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology 2002; 35:762771.
  • 100
    Ikejima K, Takei Y, Honda H, Hirose M, Yoshikawa M, Zhang YJ, Lang T, et al. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 2002; 122:13991410.
  • 101
    Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, et al. The hormone resistin links obesity to diabetes. Nature 2001; 409:307312.
  • 102
    Kondo M, Shimomura I, Matsukawa Y, Kumada K, Takahashi M, Matsuda M, Ouchi N, et al. Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. Diabetes 2002; 51:23252328.
  • 103
    Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001; 7:947953.
  • 104
    Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A. Plasma transforming growth factor-β1 level and efficacy of α-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 2001; 15:16671672.
  • 105
    Robertson G, Leclercq I, Farrell GC. Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol 2001; 281:G1135G1139.
  • 106
    Nanji AA, Jokelainen K, Tipoe GL, Rahemtulla A, Dannenberg AJ. Dietary saturated fatty acids reverse inflammatory and fibrotic changes in rat liver despite continued ethanol administration. J Pharmacol Exp Ther 2001; 299:638644.
  • 107
    Fisher EA, Ginsberg HN. Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins. J Biol Chem 2002; 277:1737717380.
  • 108
    Mensenkamp AR, Teusink B, Baller JF, Wolters H, Havinga R, van Dijk KW, Havekes LM, et al. Mice expressing only the mutant APOE3Leiden gene show impaired VLDL secretion. Arterioscler Thromb Vasc Biol 2001; 21:13661372.
  • 109
    Davidson NO, Shelness GS. Apolipoprotein B: mRNA editing, lipoprotein assembly, and presecretory degradation. Annu Rev Nutr 2000; 20:169193.
  • 110
    Leung GK, Veniant MM, Kim SK, Zlot CH, Raabe M, Bjorkegren J, Neese RA, et al. A deficiency of microsomal triglyceride transfer protein reduces apolipoprotein B secretion. J Biol Chem 2000; 275:75157520.
  • 111
    Bernard S, Touzet S, Personne I, Lapras V, Bondon PJ, Berthezène F, Moulin P. Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with type II diabetes. Diabetologia 2000; 43:995999.
  • 112
    Bjorkegren J, Beigneux A, Bergo MO, Maher JJ, Young SG. Blocking the secretion of hepatic very low density lipoproteins renders the liver more susceptible to toxin-induced injury. J Biol Chem 2002; 277:54765483.
  • 113
    Charlton M, Sreekumar R, Rasmussen D, Lindor K, Nair KS. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology 2002; 35:898904.
  • 114
    Garg A, Misra A. Hepatic steatosis, insulin resistance, and adipose tissue disorders. J Clin Endocrinol Metab 2002; 87:30193022.
  • 115
    Agarwal AK, Arioglu E, De Almeida S, Akkoc N, Taylor SI, Bowcock AM, Barnes RI, et al. AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34. Nat Genet 2002; 31:2123.
  • 116
    Agarwal AK, Garg A. A novel heterozygous mutation in peroxisome proliferator-activated receptor-γ gene in a patient with familial partial lipodystrophy. J Clin Endocrinol Metab 2002; 87:408411.
  • 117
    Shackleton S, Lloyd DJ, Jackson SN, Evans R, Niermeijer MF, Singh BM, Schmidt H, et al. LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nat Genet 2000; 24:153156.
  • 118
    Shimano H, Horton JD, Hammer RE, Shimomura I, Brown MS, Goldstein JL. Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a. J Clin Invest 1996; 98:15751584.
  • 119
    Yahagi N, Shimano H, Hasty AH, Matsuzaka T, Ide T, Yoshikawa T, Amemiya-Kudo M, et al. Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice. J Biol Chem 2002; 277:1935319357.
  • 120
    Arioglu Oral E, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, Wagner AJ, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002; 346:570578.
  • 121
    Dianzani MU. Uncoupling of oxidative phosphorylation in mitochondria from fatty livers. Biochim Biophys Acta 1954; 14:514532.
  • 122
    Dianzani MU. The content of adenosine polyphosphates in fatty livers. Biochem J 1957; 65:116124.
  • 123
    Vendemiale G, Grattagliano I, Caraceni P, Caraccio G, Domenicali M, Dall'Agata M, Trevisani F, et al. Mitochondrial oxidative injury and energy metabolism alteration in rat fatty liver: effect of the nutritional status. Hepatology 2001; 33:808815.
  • 124
    Cortez-Pinto H, Chatham J, Chacko VP, Arnold C, Rashid A, Diehl AM. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA 1999; 282:16591664.
  • 125
    Baffy G, Zhang C-Y, Glickman JN, Lowell BB. Obesity-related fatty liver is unchanged in mice deficient for mitochondrial uncoupling protein 2. Hepatology 2002; 35:753761.
  • 126
    Grove J, Daly AK, Bassendine MF, Day CP. Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. Hepatology 1997; 26:143146.
  • 127
    Valenti L, Fracanzani AL, Dongiovanni P, Santorelli G, Branchi A, Taioli E, Fiorelli G, et al. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 2002; 122:274280.
  • 128
    Day C. CD14 promoter polymorphism associated with risk of NASH. J Hepatol 2002; 36(Suppl 1):21.
  • 129
    Järveläinen HA, Orpana A, Perola M, Savolainen VT, Karhunen PJ, Lindros KO. Promoter polymorphism of the CD14 endotoxin receptor gene as a risk factor for alcoholic liver disease. Hepatology 2001; 33:11481153.
  • 130
    Koteish A, Diehl AM. Animal models of steatosis. Semin Liver Dis 2001; 21:89104.
  • 131
    Cohen P, Zhao C, Cai X, Montez JM, Rohani SC, Feinstein P, Mombaerts P, et al. Selective deletion of leptin receptor in neurons leads to obesity. J Clin Invest 2001; 108:11131121.
  • 132
    Heiman ML, Ahima RS, Craft LS, Schoner B, Stephens TW, Flier JS. Leptin inhibition of the hypothalamic-pituitary-adrenal axis in response to stress. Endocrinology 1997; 138:38593863.
  • 133
    Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001; 294:21662170.
  • 134
    Lu SC, Alvarez L, Huang ZZ, Chen L, An W, Corrales FJ, Avila MA, et al. Methionine adenosyltransferase 1A knockout mice are predisposed to liver injury and exhibit increased expression of genes involved in proliferation. Proc Natl Acad Sci U S A 2001; 98:55605565.
  • 135
    Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346:12211231.
  • 136
    Klein S, Wadden T, Sugerman HJ. AGA technical review on obesity. Gastroenterology 2002; 123:882932.
  • 137
    Pouliot MC, Despres JP, Lemieux S, Moorjani S, Bouchard C, Tremblay A, Nadeau A, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 1994; 73:460468.
  • 138
    Brodkin CA, Daniell W, Checkoway H, Echeverria D, Johnson J, Wang K, Sohaey R, et al. Hepatic ultrasonic changes in workers exposed to perchloroethylene. Occup Environ Med 1995; 52:679685.
  • 139
    Redlich CA, Cullen MR. Nonalcoholic steatohepatitis. Ann Intern Med 1997; 127:410.
  • 140
    Saksena S, Johnson J, Ouiff SP, Elias E. Diet and exercise: important first steps in therapy of NASH [Abstract]. Hepatology 1999; 30:436A.
  • 141
    Bertram SR, Venter I, Stewart RI. Weight loss in obese women—exercise v. dietary education. S Afr Med J 1990; 78:1518.
  • 142
    Eden KB, Orleans CT, Mulrow CD, Pender NJ, Teutsch SM. Does counseling by clinicians improve physical activity? A summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 137:208215.
  • 143
    Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344:13431350.
  • 144
    Jones NL, Killian KJ. Exercise limitation in health and disease. N Engl J Med 2000; 343:632641.
  • 145
    van Baak MA. Exercise training and substrate utilisation in obesity. Int J Obes Relat Metab Disord 1999; 23:S11S17.
  • 146
    Hoppeler H. Skeletal muscle substrate metabolism. Int J Obes Relat Metab Disord 1999; 23:S7S10.
  • 147
    Eriksson S, Eriksson K-F, Bondesson L. Nonalcoholic steatohepatitis in obesity: a reversible condition. Acta Med Scand 1986; 220:8388.
  • 148
    Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, Torimura T, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997; 27:103107.
  • 149
    Keeffe EB, Adesman PW, Stenzel P, Palmer RM. Steatosis and cirrhosis in an obese diabetic. Resolution of fatty liver by fasting. Dig Dis Sci 1987; 32:441445.
  • 150
    Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990; 99:14081413.
  • 151
    Rozental P, Biava C, Spencer H, Zimmerman HJ. Liver morphology and function tests in obesity and during total starvation. Am J Dig Dis 1967; 12:198208.
  • 152
    Drenick EJ, Simmons F, Murphy JF. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small bowel bypass. N Engl J Med 1970; 282:829834.
  • 153
    Andersen T, Gluud C, Franzmann M-B, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 1991; 12:224229.
  • 154
    Vajro P, Fontanella A, Perna C, Orso G, Tedesco M, De Vincenzo A. Persistent hyperaminotransferasemia resolving after weight reduction in obese children. J Pediatr 1994; 125:239241.
  • 155
    Vajro P, Franzese A, Valerio G, Iannucci MP, Aragione N. Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children. J Pediatr 2000; 136:739743.
  • 156
    Kraus WE, Houmard JA, Duscha BD, Knetzger KJ, Wharton MB, McCartney JS, Bales CW, et al. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med 2002; 347:14831492.
  • 157
    Spieth LE, Harnish JD, Lenders CM, Raezer LB, Pereira MA, Hangen SJ, Ludwig DS. A low-glycemic index diet in the treatment of pediatric obesity. Arch Pediatr Adolesc Med 2000; 154:947951.
  • 158
    Vessby B. Dietary fat and insulin action in humans. Br J Nutr 2000; 83:S91S96.
  • 159
    Kurihara T, Adachi Y, Yamagata M, Abe K, Akimoto M, Hashimoto H, Ishiguro H, et al. Role of eicosapentaenoic acid in lipid metabolism in the liver, with special reference to experimental fatty liver. Clin Ther 1994; 16:830837.
  • 160
    Nanji AA, Sadrzadeh SM, Yang EK, Fogt F, Meydani M, Dannenberg AJ. Dietary saturated fatty acids: a novel treatment for alcoholic liver disease. Gastroenterology 1995; 109:547554.
  • 161
    Lokesh B, LiCari J, Kinsella JE. Effect of different dietary triglycerides on liver fatty acids and prostaglandin synthesis by mouse peritoneal cells. JPEN J Parenter Enteral Nutr 1992; 16:316321.
  • 162
    Lanza-Jacoby S, Smythe C, Phetteplace H, Tabares A. Adaptation to a fish oil diet before inducing sepsis in rats prevents fatty infiltration of the liver. JPEN J Parenter Enteral Nutr 1992; 16:353358.
  • 163
    Kolanowski J. A risk-benefit assessment of anti-obesity drugs. Drug Safety 1999; 20:119131.
  • 164
    Harrison SA, Fincke C, Helinski D, Torgerson S. Orlistat treatment in obese, non-alcoholic steatohepatitis patients: a pilot study [Abstract]. Hepatology 2002; 36:406A.
  • 165
    Mun EC, Blackburn GL, Matthews JB. Current status of medical and surgical therapy for obesity. Gastroenterology 2001; 120:669681.
  • 166
    Luyckx FH, Desaive C, Thiry A, Dewé W, Scheen AJ, Gielen JE, Lefébvre PJ. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 1998; 22:222226.
  • 167
    Silverman EM, Sapala JA, Appelman HD. Regression of hepatic steatosis in morbidly obese persons after gastric bypass. Am J Clin Pathol 1995; 104:2331.
  • 168
    Ackerman NB. Protein supplementation in the management of degenerating liver function after jejunoileal bypass. Surg Gynecol Obstetr 1979; 149:814.
  • 169
    Drenick EJ, Fisler J, Johnson D. Hepatic steatosis after intestinal bypass—prevention and reversal by metronidazole, irrespective of protein-calorie malnutrition. Gastroenterology 1982; 82:535548.
  • 170
    Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, Rakela J, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996; 23:14641467.
  • 171
    Guma G, Viola L, Thomé M, Galdame O, Alverez E. Ursodeoxycholic acid in the treatment of nonalcoholic steatohepatitis: results of a prospective clinical controlled trial [Abstract]. Hepatology 1997; 26:387A.
  • 172
    Ceriani R, Bunati S, Morini L, Sacchi E, Colombo G. Effect of ursodeoxycholic acid plus diet in patients with nonalcoholic steatohepatitis (abstract). Hepatology 1998; 28:386A.
  • 173
    Mendez-Sanchez N, Gonzalez V, Pichardo-Bahena R, Uribe M. Weight reduction and ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial [Abstract]. Hepatology 2002; 36:412A.
  • 174
    Antosiewicz J, Nishizawa Y, Liu X, Usukura J, Wakabayashi T. Suppression of the hydrazine-induced formation of megamitochondria in the rat liver by alpha-tocopherol. Exp Mol Pathol 1994; 60:173187.
  • 175
    Soltys K, Dikdan G, Koneru B. Oxidative stress in fatty livers of obese Zucker rats: rapid amelioration and improved tolerance to warm ischemia with tocopherol. Hepatology 2001; 34:1318.
  • 176
    Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000; 136:734738.
  • 177
    Alvaro D, Gigliozzi A, Piat C, Carli L, Bini A, La Rosa T, Furfaro S, et al. Effect of S-adenosyl-L-methionine on ethanol cholestasis and hepatotoxicity in isolated perfused rat liver. Dig Dis Sci 1995; 40:15921600.
  • 178
    Lu SC. Methionine adenosyltransferase and liver disease: it's all about SAM. Gastroenterology 1998; 114:403407.
  • 179
    Colell A, Garcia-Ruiz C, Morales A, Ballesta A, Ookhtens M, Rodes J, Kaplowitz N, et al. Transport of reduced glutathione in hepatic mitochondria and mitoplasts from ethanol-treated rats: effect of membrane physical properties and S-adenosyl-L-methionine. Hepatology 1997; 26:699708.
  • 180
    Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001; 96:27112717.
    Direct Link:
  • 181
    Gulbahar O, Karasu ZA, Ersoz G, Akarca US, Musoglu A. Treatment of nonalcoholic steatohepatitis with N-acetylcysteine [Abstract]. Gastroenterology 2000; 118:A1444.
  • 182
    Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345:15831592.
  • 183
    Venkataramanan R, Ramachandran V, Komoroski BJ, Zhang S, Schiff PL, Strom SC. Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures. Drug Metab Dispos 2000; 28:12701273.
  • 184
    Fu CS, Esrason K, Alshak NS, Conteas CN, Simmons VJ. Dietary lecithin, anti-oxidant and vitamin B complex (LAB) decrease hepatic steatosis in patients with NASH [Abstract]. Gastroenterology 1998; 114:A1243.
  • 185
    Azuma Y, Shinohara M, Wang PL, Hidaka A, Ohura K. Histamine inhibits chemotaxis, phagocytosis, superoxide anion production, and the production of TNFalpha and IL-12 by macrophages via H2-receptors. Int Immunopharmacol 2001; 1:18671875.
  • 186
    Villa RF, Gorini A. Pharmacology of lazaroids and brain energy metabolism: a review. Pharm Rev 1997; 49:99136.
  • 187
    Facchini FS, Hua NW, Stoohs RA. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology 2002; 122:931939.
  • 188
    DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131:281303.
  • 189
    Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001; 96:519525.
    Direct Link:
  • 190
    Acosta RC, Molina EG, O'Brien CB, Cobo MC, Amaro R, Neff GW, Schiff ER. The use of pioglitazone in nonalcoholic steatohepatitis [Abstract]. Gastroenterology 2001; 120:A546.
  • 191
    Neuschwander-Tetri BA, Brunt EM, Bacon BR, Sponseller C, Wehmeier KR, Hampton K. Histological improvement in NASH following increased insulin sensitivity with the PPAR-γ ligand rosiglitazone for 48 weeks [Abstract]. Hepatology 2002; 36:379A.
  • 192
    Galli A, Crabb DW, Ceni E, Salzano R, Mello T, Svegliati-Baroni G, Ridolfi F, et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 2002; 122:19241940.
  • 193
    Azuma T, Tomita K, Kato S, Adachi M, Inokuchi N, Kitamura N, Nishimura T, et al. A pilot study of a thiazolidinediones, pioglitazone, in nonalcoholic steatohepatitis [Abstract]. Hepatology 2002; 36:406A.
  • 194
    Sanyal AJ, Contos MJ, Sargeant C, Stravitz RT, Luketic VA, Sterling RK, Shiffman ML. A randomized controlled pilot study of pioglitazone and vitamin E versus vitamin E for non-alcoholic steatohepatitis [Abstract]. Hepatology 2002; 36:A382.
  • 195
    Vamecq J, Latruffe N. Medical significance of peroxisome proliferator-activated receptors. Lancet 1999; 354:141148.
  • 196
    Ribon V, Johnson JH, Camp HS, Saltiel AR. Thiazolidinediones and insulin resistance: peroxisome proliferator-activated receptor γ activation stimulates expression of the CAP gene. Proc Natl Acad Sci U S A 1998; 95:1475114756.
  • 197
    Kelly IE, Han TS, Walsh K, Lean ME. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 1999; 22:288293.
  • 198
    Lenhard JM, Kliewer SA, Paulik MA, Plunket KD, Lehmann JM, Weiel JE. Effects of troglitazone and metformin on glucose and lipid metabolism: alterations of two distinct molecular pathways. Biochem Pharmacol 1997; 54:801808.
  • 199
    Aubert J, Champigny O, Saint-Marc P, Negrel R, Collins S, Ricquier D, Ailhaud G. Up-regulation of UCP-2 gene expression by PPAR agonists in preadipose and adipose cells. Biochem Biophys Res Commun 1997; 238:606611.
  • 200
    Arioglu E, Duncan-Morin J, Sebring N, Rother KI, Gottlieb N, Lieberman J, Herion D, et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 2000; 133:263274.
  • 201
    Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000; 6:9981003.
  • 202
    Coyle WJ, Delaney N, Yoshihashi A, Lawson P. Metformin treatment in patients with nonalcoholic steatohepatitis normalizes LFTs and improves histology [Abstract]. Gastroenterology 1999; 116:A1198.
  • 203
    Urso R, Visco-Comandini U. Metformin in non-alcoholic steatohepatitis [Letter]. Lancet 2002; 359:355356.
  • 204
    Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis [Letter]. Lancet 2001; 358:893894.
  • 205
    Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108:11671174.
  • 206
    Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, for the Stop-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359:20722077.
  • 207
    Santomauro AT, Boden G, Silva ME, Rocha DM, Santos RF, Ursich MJ, Strassmann PG, et al. Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes 1999; 48:18361841.
  • 208
    Nestler JE, Jakubowicz DJ, Iuorno MJ. Role of inositolphosphoglycan mediators of insulin action in the polycystic ovary syndrome. J Pediatr Endocrinol 2000; 13:12951298.
  • 209
    Saibara T, Onishi S, Ogawa Y, Yoshida S, Enzan H. Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis [Letter]. Lancet 1999; 353:1802.
  • 210
    Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis [Letter; Comment]. J Hepatol 1999; 31:384.
  • 211
    Horlander JC, Kwo PY, Cummings OW, Koukoulis G. Atorvastatin for the treatment of NASH [Abstract]. Gastroenterology 2001; 120:A544.
  • 212
    Nair S, Wiseman M. HMG-CoA reductase inhibitors in no alcoholic fatty liver disease: is their potential hepatotoxicity an issue in these patients? A case control study based on histology [Abstract]. Hepatology 2002; 36:409A.
  • 213
    Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, Kimura BJ, Vladutiu GD, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002; 137:581585.
  • 214
    Mensenkamp AR, Havekes LM, Romijn JA, Kuipers F. Hepatic steatosis and very low density lipoprotein secretion: the involvement of apolipoprotein E. J Hepatol 2001; 35:816822.
  • 215
    Czaja AJ. Recurrence of nonalcoholic steatohepatitis after liver transplantation [Editorial]. Liver Transplant Surg 1997; 3:185186.
  • 216
    Molloy RM, Komorowski R, Varma RR. Recurrent nonalcoholic steatohepatitis and cirrhosis after liver transplantation. Liver Transplant Surg 1997; 3:177178.
  • 217
    Carson K, Washington MK, Treem WR, Clavien PA, Hunt CM. Recurrence of nonalcoholic steatohepatitis in a liver transplant recipient. Liver Transplant Surg 1997; 3:174176.
  • 218
    Kim WR, Poterucha JJ, Porayko MK, Dickson ER, Steers JL, Wiesner RH. Recurrence of nonalcoholic steatohepatitis following liver transplantation. Transplantation 1996; 62:18021805.
  • 219
    Cassarino DS, Swerdlow RH, Parks JK, Parker WD Jr, Bennett JP Jr. Cyclosporin A increases resting mitochondrial membrane potential in SY5Y cells and reverses the depressed mitochondrial membrane potential of Alzheimer's disease cybrids. Biochem Biophys Res Commun 1998; 248:168173.
  • 220
    Cassarino DS, Swerdlow RH, Parks JK, Parker WD Jr, Bennett JP Jr. Nonalcoholic Steatohepatitis Clinical Research Network. Hepatology 2003; 37:244.
  • 221
    Brunt EM, Janney CJ, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Non-alcoholic steatohepatitis: a proposal for grading and staging the histologic lesions. Am J Gastroenterol 1999; 94:24672474.
    Direct Link:
  • 222
    Sozo A, Arrese M, Glasinovic JC. Evidence of intestinal bacterial overgrowth in patients with NASH [Abstract]. Gastroenterology 2001; 120:A118.
  • 223
    Bogomolov P, Petrakov A, Vereshagina V, Isakov V. Abnormal hydrogen breath test in patients with NASH [Abstract]. AASLD Syllabus Single Topic Conference Nonalcoholic Steatohepatitis, September 20–22, 2002. Atlanta, GA.
  • 224
    Al-Osaimi AMS, Caldwell SH. Intermittent disconjugate gaze: a novel finding in nonalcoholic steatohepatitis and cryptogenic cirrhosis [Abstract]. Hepatology 2002; 36:408A.
  • 225
    Guillausseau P-J, Massin P, Dubois-Laforgue D, Timsit J, Virally M, Gin H, Bertin E, et al. Maternally inherited diabetes and deafness: a multicenter study. Ann Intern Med 2001; 134:721728.
  • 226
    Caldwell SH, Hespenheide EE. Subacute liver failure in obese women. Am J Gastroenterol 2002; 97:20582062.
    Direct Link:
  • 227
    Diehl AM, Goodman Z, Ishak KG. Alcohol-like liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology 1988; 95:10561062.
  • 228
    Nagore N, Scheuer PJ. Does a linear pattern of sinusoidal IgA deposition distinguish between alcoholic and diabetic liver disease? Liver 1988; 8:281286.
  • 229
    Tumiel M, Whitcomb BJ, Krawitt EL. Circulating antinuclear antibodies in patients with nonalcoholic steatohepatitis [Abstract]. Hepatology 1994; 20:409A.
  • 230
    Tajiri K, Takenawa H, Yamaoka K, Yamane M, Marumo F, Sato C. Nonalcoholic steatohepatitis masquerading as autoimmune hepatitis. J Clin Gastroenterol 1997; 25:538540.
  • 231
    Bonkovsky HL, Jawaid Q, Tortorelli K, LeClair P, Cobb J, Lambrecht RW, Banner BF. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol 1999; 31:421429.
  • 232
    George DK, Goldwurm S, MacDonald GA, Cowley LL, Walker NI, Ward PJ, Jazwinska EC, et al. Increased hepatic iron in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998; 114:311318.
  • 233
    Younossi ZM, Gramlich T, Bacon BR, Matteoni CA, Boparai N, O'Neill R, McCullough AJ. Hepatic iron and nonalcoholic fatty liver disease. Hepatology 1999; 30:847850.
  • 234
    Siegelman ES, Rosen MA. Imaging of hepatic steatosis. Semin Liver Dis 2001; 21:7180.
  • 235
    Franzese A, Vajro P, Argenziano A, Puzziello A, Iannucci MP, Saviano MC, Brunetti F, et al. Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig Dis Sci 1997; 42:14281432.
  • 236
    Obinata K, Maruyama T, Hayashi M, Watanabe T, Nittono H. Effect of taurine on the fatty liver of children with simple obesity. Adv Exp Med Biol 1996; 403:607613.
  • 237
    Day CP, James OF. Steatohepatitis: a tale of two “hits”? [Editorial] Gastroenterology 1998; 114:842845.